Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Galsky, Matthew; Arranz Arija, Jose; Bamias, Aristotelis; Davis, Ian; De Santis, Maria; Kikuchi, Eiji; Garcia-del-Muro, Xavier; De Giorgi, Ugo; Mencinger, Marina; Izumi, Kouji; Panni, Stefano; GÜMÜŞ, MAHMUT; ÖZGÜROĞLU, Mustafa; Kalebasty, Arash; Park, Se; Alekseev, Boris; Schutz, Fabio; Li, Jian-Ri; Ye, Dingwei; Vogelzang, Nicholas; Bernhard, Sandrine; Tayama, Darren; Mariathasan, Sanjeev; Mecke, Almut; Thastrom, AnnChristine; Grande, Enrique

doi:10.1016/s0140-6736(20)30230-0

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Galsky M. D., Arranz Arija J. A., Bamias A., Davis I. D., De Santis M., Kikuchi E., ...More

LANCET, vol.395, no.10236, pp.1547-1557, 2020 (SCI-Expanded)

Publication Type: Article / Article
Volume: 395 Issue: 10236
Publication Date: 2020
Doi Number: 10.1016/s0140-6736(20)30230-0
Journal Name: LANCET
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Agricultural & Environmental Science Database, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Psycinfo, Veterinary Science Database
Page Numbers: pp.1547-1557
Istanbul University Affiliated: No

Abstract

Background Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma.